Score Card for WuXi PharmaTech (WX)

 WuXi PharmaTech
Shares Outstanding (MRQ): 74.59 mill
Fully diluted shares outstanding (most recent quarter, SEC filing)
POSITIVE: under 30 million shares  |  NEGATIVE: over 50 million shares
New Shares / Dilution (TTM): 1.44 mill1.97%
Newly issued shares in the past 12 months (most recent quarter, SEC filing)
POSITIVE: under 10% dilution  |  NEGATIVE: over 30% dilution
Cash (MRQ): 79.12 mill0.00%
Cash and cash equivalents, excl. restricted cash (most recent quarter, SEC filing)
POSITIVE: over 30% of market capitalization  |  NEGATIVE: under 10% of market capitalization
Account Receivables (MRQ): 57.71 mill0.00%
Account/Trade receivables (most recent quarter, SEC filing)
POSITIVE: under 10% of market capitalization  |  NEGATIVE: over 30% of market capitalization
Account Receivables (Q/Q): -0.60 mill 
Quarterly increase/decrease of account/trade receivables (most recent quarter, SEC filing)
POSITIVE: quarterly decrease  |  NEGATIVE: quarterly increase of 20% or more
Relevant only if A/R to market capitalization ration higher than 10%
Long-Term Debt (MRQ): 45.76 mill0.00%
Long-term debt excl. warrant liabilities (most recent quarter, SEC filing)
POSITIVE: under 5% of market capitalization  |  NEGATIVE: over 20% of market capitalization
Revenue Growth (Q/Q): 0.54% 
Revenue Growth (Y/Y): 21.04% 
Total revenue growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 30% revenue growth  |  NEGATIVE: negative revenue growth
Net Income Growth (Q/Q): 8.74% 
Net Income Growth (Y/Y): 11.76% 
Net income growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 20% net income growth  |  NEGATIVE: negative net income growth
EPS Growth (Y/Y): 9.60% 
EPS growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 10% EPS growth  |  NEGATIVE: negative EPS growth
EPS | P/E (2 MRQ Projection): $1.020.00 
Projected trailing annual EPS using the two most recently reported quarters
POSITIVE: P/E under 6 / 8 / 10  |  NEGATIVE: P/E over 12
Price/Sales (2 MRQ Projection): 0.00
Projected trailing annual sales using the two most recently reported quarters
POSITIVE: Price/Sales ratio under 1.25  |  NEGATIVE: Price/Sales ratio over 2.5
Price/Book (MRQ): 0.00 
Market capitalization / total stockholders' equity (most recent quarter, SEC filing)
POSITIVE: Price/Book ratio under 1.25  |  NEGATIVE: Price/Book ratio over 2.5
Recent High | Trading near Highs: $15.19-100.00% 
Difference between current price and recent (3-6 months) high
POSITIVE: current price within 20% of recent highs
Recent Low | Trading near Lows: $13.00-100.00%
Difference between current price and recent (3-6 months) low
NEGATIVE: current price within 20% of recent lows
Forward EPS | P/E Projection (Estimates): $1.470.00 
Projected forward EPS (Trading China estimates)
POSITIVE: P/E under 4 / 6 / 8  |  NEGATIVE: P/E over 10
Auditor: Deloitte Touche
The Company's independent registered public accounting firm
POSITIVE: Top 10 ranked  |  NEGATIVE: not ranked in the Top 100
WX
Healthcare & Drugs
SCORE
2
READ: Score Cards Explained
Current Price:  n/a
2008 Close: -100.00%$19.60
2009 Close: -100.00%$15.96
High (2012-08-14): -100.00%$15.19
Low (2012-07-27): -100.00%$13.00
Market Capitalization: n/a
Last Quarter: 2010-06-30
Revenue (MRQ): 81.04 mill
Net Income (MRQ): 19.91 mill
all financial data provided without warranty